biote Corp (BTMD)vsEli Lilly and Company (LLY)
BTMD
biote Corp
$2.10
-0.85%
HEALTHCARE · Cap: $77.86M
LLY
Eli Lilly and Company
$1,117.26
+0.92%
HEALTHCARE · Cap: $1.01T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 38297% more annual revenue ($72.25B vs $188.16M). LLY leads profitability with a 35.0% profit margin vs 8.3%. BTMD trades at a lower P/E of 5.1x. LLY earns a higher WallStSmart Score of 76/100 (B+).
BTMD
Hold35
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+47.8%
Fair Value
$4.06
Current Price
$2.10
$1.96 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 8.3%
Earnings declined 83.8%
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : BTMD
The strongest argument for BTMD centers on P/E Ratio, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : BTMD
The primary concerns for BTMD are Market Cap, Return on Equity, Revenue Growth.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
BTMD profiles as a value stock while LLY is a growth play — different risk/reward profiles.
BTMD carries more volatility with a beta of 1.66 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 35/100), backed by strong 35.0% margins and 55.5% revenue growth. BTMD offers better value entry with a 47.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
biote Corp
HEALTHCARE · MEDICAL CARE FACILITIES · USA
biote corp. The company is headquartered in Irvine, Texas.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?